Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment
Emergency use authorization of drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by regulatory authorities has provided new options to treat high-risk outpatients with mild-to-moderate Coronavirus disease 2019 (COVID-19). We conducted an ambispective cohort study of patients...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643502/ https://www.ncbi.nlm.nih.gov/pubmed/36388947 http://dx.doi.org/10.3389/fmed.2022.1036473 |
_version_ | 1784826542147239936 |
---|---|
author | Lasagna, Angioletta Cassaniti, Irene Lilleri, Daniele Quaccini, Mattia Ferrari, Alessandra Sacchi, Paolo Bruno, Raffaele Baldanti, Fausto Pedrazzoli, Paolo |
author_facet | Lasagna, Angioletta Cassaniti, Irene Lilleri, Daniele Quaccini, Mattia Ferrari, Alessandra Sacchi, Paolo Bruno, Raffaele Baldanti, Fausto Pedrazzoli, Paolo |
author_sort | Lasagna, Angioletta |
collection | PubMed |
description | Emergency use authorization of drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by regulatory authorities has provided new options to treat high-risk outpatients with mild-to-moderate Coronavirus disease 2019 (COVID-19). We conducted an ambispective cohort study of patients with solid tumors on active treatment to examine the effectiveness of these drugs in preventing the progression to severe COVID-19. Sixty-nine patients with solid tumors (43 women, 26 men; median age 61, range 26–80) reported a laboratory-confirmed diagnosis of SARS-CoV-2 infection. Forty-nine patients received early therapy. Only one patient (14.5%) required hospitalization for COVID-19. As for safety, two patients (5.9%) reported nausea during nirmatrelvir/ritonavir. The majority of treated patients showed a reduced time to negative sample (73 vs. 18%, p = 0.0011) and shorter symptoms’ duration (94 vs. 27%; p < 0.0001) compared to the patients not treated with the early COVID-19 therapies. Our data suggest that early therapies may reduce the morbidity of COVID-19 in patients with solid tumors. |
format | Online Article Text |
id | pubmed-9643502 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96435022022-11-15 Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment Lasagna, Angioletta Cassaniti, Irene Lilleri, Daniele Quaccini, Mattia Ferrari, Alessandra Sacchi, Paolo Bruno, Raffaele Baldanti, Fausto Pedrazzoli, Paolo Front Med (Lausanne) Medicine Emergency use authorization of drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by regulatory authorities has provided new options to treat high-risk outpatients with mild-to-moderate Coronavirus disease 2019 (COVID-19). We conducted an ambispective cohort study of patients with solid tumors on active treatment to examine the effectiveness of these drugs in preventing the progression to severe COVID-19. Sixty-nine patients with solid tumors (43 women, 26 men; median age 61, range 26–80) reported a laboratory-confirmed diagnosis of SARS-CoV-2 infection. Forty-nine patients received early therapy. Only one patient (14.5%) required hospitalization for COVID-19. As for safety, two patients (5.9%) reported nausea during nirmatrelvir/ritonavir. The majority of treated patients showed a reduced time to negative sample (73 vs. 18%, p = 0.0011) and shorter symptoms’ duration (94 vs. 27%; p < 0.0001) compared to the patients not treated with the early COVID-19 therapies. Our data suggest that early therapies may reduce the morbidity of COVID-19 in patients with solid tumors. Frontiers Media S.A. 2022-10-26 /pmc/articles/PMC9643502/ /pubmed/36388947 http://dx.doi.org/10.3389/fmed.2022.1036473 Text en Copyright © 2022 Lasagna, Cassaniti, Lilleri, Quaccini, Ferrari, Sacchi, Bruno, Baldanti and Pedrazzoli. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Lasagna, Angioletta Cassaniti, Irene Lilleri, Daniele Quaccini, Mattia Ferrari, Alessandra Sacchi, Paolo Bruno, Raffaele Baldanti, Fausto Pedrazzoli, Paolo Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment |
title | Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment |
title_full | Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment |
title_fullStr | Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment |
title_full_unstemmed | Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment |
title_short | Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment |
title_sort | effectiveness of the available early therapies in reducing severe covid-19 in non-hospitalized patients with solid tumors on active treatment |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643502/ https://www.ncbi.nlm.nih.gov/pubmed/36388947 http://dx.doi.org/10.3389/fmed.2022.1036473 |
work_keys_str_mv | AT lasagnaangioletta effectivenessoftheavailableearlytherapiesinreducingseverecovid19innonhospitalizedpatientswithsolidtumorsonactivetreatment AT cassanitiirene effectivenessoftheavailableearlytherapiesinreducingseverecovid19innonhospitalizedpatientswithsolidtumorsonactivetreatment AT lilleridaniele effectivenessoftheavailableearlytherapiesinreducingseverecovid19innonhospitalizedpatientswithsolidtumorsonactivetreatment AT quaccinimattia effectivenessoftheavailableearlytherapiesinreducingseverecovid19innonhospitalizedpatientswithsolidtumorsonactivetreatment AT ferrarialessandra effectivenessoftheavailableearlytherapiesinreducingseverecovid19innonhospitalizedpatientswithsolidtumorsonactivetreatment AT sacchipaolo effectivenessoftheavailableearlytherapiesinreducingseverecovid19innonhospitalizedpatientswithsolidtumorsonactivetreatment AT brunoraffaele effectivenessoftheavailableearlytherapiesinreducingseverecovid19innonhospitalizedpatientswithsolidtumorsonactivetreatment AT baldantifausto effectivenessoftheavailableearlytherapiesinreducingseverecovid19innonhospitalizedpatientswithsolidtumorsonactivetreatment AT pedrazzolipaolo effectivenessoftheavailableearlytherapiesinreducingseverecovid19innonhospitalizedpatientswithsolidtumorsonactivetreatment |